MILabs

We are thrilled to announce that we will be exhibiting at the upcoming American Society for Bone and Mineral Research (ASBMR) Annual Meeting.    Visit us at Booth #215 to discuss your research applications and explore how our advanced imaging solutions can elevate your work to new heights.   We look forward to connecting with you and discovering how we can support your research endeavors.   See you at #ASBMR! #MILabs #CT #SPECT #OI #Bioluminescence #Flourescence #ASMBMR2024 #PreclinicalImaging, #radiology #Imaging #invivo #prostheticimaging #prosthetics #Bone #Musculoskeltal

As the WMIC Exhibition wraps up today, there's still time to stop by our booth 207! Don't miss the opportunity to discover how our innovative solutions can streamline your work and drive success. We look forward to connecting and discussing how we can help achieve your goals. #MILabs #VECTor #PET #SPECT #CT #Optical #WMIC #MOMIL #preclinicalimaging #multimodal #preclinicalresearch #molecularimaging #nuclearmedicine

Thank you to everyone who visited our booth yesterday! The energy and interest were incredible, and our entire team is excited to continue connecting with you. If you haven’t stopped by yet, we’d love to meet you to learn about your exciting research findings and plans. Let’s exchange insights while sharing some of our latest technological developments that could strengthen your work. Don’t miss out—come visit us at booth #207 – we can’t wait to connect with you! #MILabs #VECTor #PET #SPECT #CT #Optical #WMIC #MOMIL #preclinicalimaging #multimodal #preclinicalresearch #molecularimaging #nuclearmedicine

We’re excited to welcome you to our booth #207 at #WMIC24! Come visit us at Booth #207 to share your exciting research findings and discuss your plans with our team.  We look forward to learning from you and sharing some of our latest insights as well! See you there soon! #MILabs #VECTor #PET #SPECT #CT #Optical #WMIC #MOMIL #preclinicalimaging #multimodal #preclinicalresearch #molecularimaging #nuclearmedicine

Excited to kick off the WMIC 2024 with an inspiring MILabs Annual User Meeting! It was fantastic to hear from our users about their innovative applications and plans across various fields of preclinical imaging research. Looking forward to connecting with many more of you during the rest of WMIC!

𝗙𝗜𝗥𝗦𝗧 𝗧𝗜𝗠𝗘 𝗘𝗩𝗘𝗥 𝙄𝙉 𝙑𝙄𝙑𝙊 𝗤𝗨𝗔𝗡𝗧𝗜𝗧𝗔𝗧𝗜𝗩𝗘 𝗦𝗣𝗘𝗖𝗧 𝗜𝗠𝗔𝗚𝗜𝗡𝗚 𝗢𝗙 𝗔𝗖𝗧𝗜𝗡𝗜𝗨𝗠-𝟮𝟮𝟲 Targeted radionuclide therapy (TRT) has shown promising clinical outcomes for cancer treatment with many combinations of isotopes, targeting vectors, and cancer types. ²²⁵Ac is a very potent therapeutic isotope due to its decay chain which consists of four high energy alpha emissions; however, there are challenges in imaging it for assessing biodistribution, pharmacokinetics, and dosimetry. On the other hand, ²²⁶Ac emits two gamma photons, 158 keV (17.5%) and 230 keV (26.9%) with suitable energy for SPECT imaging; additionally, ²²⁶Ac could be leveraged as a therapeutic isotope due to its four alpha emissions following the decay of ²²⁶Th. The main objective of this work was to assess for the first time ever the 𝘪𝘯 𝘷𝘪𝘷𝘰 capabilities of ²²⁶Ac SPECT imaging and validate the quantitative accuracy of activity measurements compared to 𝘦𝘹 𝘷𝘪𝘷𝘰 biodistribution. [²²⁶Ac]Ac³⁺ was radiolabeled with the bioconjugate crown-TATE developed for therapeutic targeting of neuroendocrine tumors (NET); mice with AR42J tumor xenografts were injected with either 2 MBq of [²²⁶Ac]Ac-crown-TATE or 4 MBq of free [²²⁶Ac]Ac³⁺ activity and were scanned at 1, 2.5, 5, and 24 h post injection with a #MILabs #VECTor system, which was used to perform the 𝘪𝘯 𝘷𝘪𝘷𝘰 quantitative ²²⁶Ac SPECT imaging and validation of activity estimation. Quantitative SPECT images were reconstructed from the 158 keV and 230 keV photopeaks with attenuation, background, and scatter corrections. In this study for the first time are presented 𝘪𝘯 𝘷𝘪𝘷𝘰 quantitative SPECT images of ²²⁶Ac activity distributions. Time-activity curves derived from SPECT images quantified the 𝘪𝘯 𝘷𝘪𝘷𝘰 biodistribution of [²²⁶Ac]Ac-crown-TATE and free [²²⁶Ac]Ac³⁺ activity. Image-based activity measurements in the tumors and organs of interest corresponded well with 𝘦𝘹 𝘷𝘪𝘷𝘰 biodistribution measurements. In conclusion, it was established the feasibility of 𝘪𝘯 𝘷𝘪𝘷𝘰 ²²⁶Ac quantitative SPECT imaging for accurate measurement of actinium biodistribution in a preclinical model. This imaging technique could facilitate more efficient development of novel actinium labelled compounds in the preclinical phase by providing accurate quantitative 𝘪𝘯 𝘷𝘪𝘷𝘰 pharmacokinetic information essential for estimating toxicities, dosimetry, and therapeutic potency. Publication in Physics in Medicine & Biology: https://lnkd.in/eY9xkiur Used imaging platform: https://lnkd.in/eCJGR-uB First author: Helena Koniar #SPECT_CT #Ac226 #theranostics #targeted_radionuclide_therapy #quantitative_SPECT #makingmolecularimagingclear #invivo #mice #UBC #TRIUMPH #preclinicalimaging

𝗟𝗔𝗣𝗢𝗡𝗜𝗧𝗘-𝗠𝗘𝗗𝗜𝗔𝗧𝗘𝗗 𝗗𝗘𝗟𝗜𝗩𝗘𝗥𝗬 𝗢𝗙 𝗕𝗠𝗣-𝟮 𝗙𝗢𝗥 𝗕𝗢𝗡𝗘 𝗧𝗜𝗦𝗦𝗨𝗘 𝗘𝗡𝗚𝗜𝗡𝗘𝗘𝗥𝗜𝗡𝗚 Autograft and allograft are the current gold standards to treat non-union fractures; however, challenges related to their availability and immune rejection highlight the need for improved treatments. One possible strategy in bone tissue engineering is to exploit specific growth factors to induce an effect on cells to change their phenotype, behavior and initiate signaling pathways which lead to increased matrix deposition and tissue formation. Bone morphogenetic protein-2 (BMP-2) is a potent osteogenic growth factor; however, given its rapid clearance time 𝘪𝘯 𝘷𝘪𝘷𝘰, there is a specific therapeutic window for efficacy while avoiding potential deleterious side-effects. The aim of this study was to investigate the use of Laponite/BMP-2 coatings as a dry, ready-to-use, biocompatible, bioactive, reliable, osteoinductive coating on 3D-printed poly(caprolactone) trimethacrylate (PCL-TMA900) resin scaffolds. A #MILabs U-CT system was used to investigate the 𝘪𝘯 𝘷𝘪𝘷𝘰 osteogenic potential of such Laponite/BMP-2 coatings. Looking at the study results, 𝘪𝘯 𝘷𝘪𝘵𝘳𝘰 experiments confirmed the cytocompatibility of the PCL-TMA900 scaffolds and effective osteogenic differentiation of C2C12 myoblast cells in response to the Laponite/BMP-2 coating. The chorioallantoic membrane (CAM) assay verified PCL-TMA900 scaffold material biocompatibility and ability to support angiogenesis. A murine subcutaneous implantation model assessed heterotopic bone formation in response to the Laponite/BMP-2 coating, when used immediately post-coating and after 24 h of room temperature storage, to evaluate a delayed use manner. The Laponite/BMP-2 coated PCL-TMA900 scaffolds implanted showed consistent, significant bone formation over the study period compared to the uncoated PCL-TMA 900 scaffold and BMP-2 only coated control scaffolds 𝘪𝘯 𝘷𝘪𝘷𝘰, indicating the ability of Laponite to bind the BMP-2 to the PCL-TMA900 scaffold. Bone formed peripherally around the Laponite/BMP-2 coated scaffold, with no aberrant bone formation observed. In conclusion, the Laponite/BMP-2 coating here presented, has shown clear efficacy 𝘪𝘯 𝘷𝘪𝘵𝘳𝘰 and 𝘪𝘯 𝘷𝘪𝘷𝘰, therefore, suggesting the use of dry Laponite/BMP-2 coated PCL-TMA900 scaffolds in osseous defect site studies. Publication in Advanced Materials Interfaces: https://lnkd.in/ec-mX-Dg Used imaging platform: https://lnkd.in/eCJGR-uB First Authors: Karen Marshall and Jonathan Wojciechowski #U_CT #bone #BMP2 #laponite #tissue_engineering #3D_printed #PCL_scaffold #makingmolecularimagingclear #invivo #mice #unisouthampton #preclinicalimaging

Join us at Booth #207, World Molecular Imaging Congress (WMIC) 2024 in Montreal! We are eager to connect and discuss your research applications in theranostics, preclinical in vivo imaging, clinical translation, and radiopharmaceutical development. Our MILabs VECTorCT platform is tailored to meet your needs, offering advanced capabilities in diagnosis and monitoring treatment across various medical and biological faculties. Whether you are focused on staging, re-staging, or pushing the boundaries of imaging technologies, we are here to collaborate and innovate together. Discover how VECTorCT can elevate your research to the next level! #WMIC2024 #Theranostics #CancerImaging #ClinicalTranslation #Radiopharmaceuticals #preclinicalimaging #nuclearmedicine #invivoimging #MILabs #multimodalimaging #molecularimaging #VECTor #PET #SPECT #CT #OpticalImaging

𝗥𝗘𝗙𝗢𝗥𝗠𝗔𝗧𝗧𝗘𝗗 𝗖𝗟𝗜𝗡𝗜𝗖𝗔𝗟 𝗘𝗚𝗙𝗥 𝗔𝗡𝗧𝗜𝗕𝗢𝗗𝗜𝗘𝗦 𝗪𝗜𝗧𝗛 𝗘𝗡𝗛𝗔𝗡𝗖𝗘𝗗 𝗡𝗘𝗨𝗧𝗥𝗢𝗣𝗛𝗜𝗟 𝗖𝗬𝗧𝗢𝗧𝗢𝗫𝗜𝗖𝗜𝗧𝗬 EGFR plays an essential role in cellular signaling pathways that regulate cell growth, proliferation, and survival and is often dysregulated in cancer. Several monoclonal IgG antibodies have been clinically tested over the years, which exert their function via blocking the ligand binding domain and inducing Fc-related effector functions. However, these IgG antibodies do not optimally recruit neutrophils, which are the most abundant white blood cell population in humans. In this study, researchers reformatted six therapeutic EGFR antibodies (cetuximab, panitumumab, nimotuzumab, necitumumab, zalutumumab, and matuzumab) into the IgA3.0 format, which is an IgA2 isotype that has been adapted for clinical application. A #MILabs OI system, in the bioluminescence (BLI) modality, was used to monitor twice a week the tumor outgrowth in A431 tumor bearing mice treated with newly reformatted IgA3.0 EGFR antibodies, with the aim to investigate if these were capable of reducing tumor outgrowth and kill tumor cells 𝘪𝘯 𝘷𝘪𝘷𝘰. Looking at the results, reformatting these antibodies preserved Fab-mediated functions such as EGFR binding, growth inhibition and ligand blockade. Additionally, whole leukocyte ADCC was significantly increased when using this panel of IgA3.0 antibodies compared to their respective IgG counterparts, with no major differences between IgA3.0 antibodies. 𝘐𝘯 𝘷𝘪𝘷𝘰, IgA3.0 matuzumab outperformed the other antibodies, resulting in the strongest suppression of tumor outgrowth in a long intraperitoneal model; it is shown that neutrophils are important for the suppression of tumor outgrowth. IgA3.0 matuzumab exhibited reduced receptor internalization compared to the other antibodies, possibly accounting for its superior 𝘪𝘯 𝘷𝘪𝘷𝘰 Fc-mediated tumor cell killing efficacy. In conclusion, reformatting EGFR antibodies into an IgA3.0 format increased Fc-mediated killing while retaining Fab-mediated functions and could therefore be a good alternative for the currently available antibody therapies. Publication in Molecular Cancer Therapeutics: https://lnkd.in/eJymi_eD Used imaging platform: https://lnkd.in/eCJGR-uB First author: Chilam Chan #bioluminescence_imaging #BLI #optical_imaging #tumor #EGFR #IgA30_antibodies #makingmolecularimagingclear #invivo #mice #UMCUtrecht #preclinicalimaging

The field of radioligand therapy is growing exponentially, bringing tremendous value to the understanding and treatment of various types of cancer. To contribute to this endeavor, MILabs is heading to Montreal to exhibit at the 𝗪𝗼𝗿𝗹𝗱 𝗠𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗜𝗺𝗮𝗴𝗶𝗻𝗴 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 (𝗪𝗠𝗜𝗖) from September 9-12. Please join us at 𝗕𝗼𝗼𝘁𝗵 #𝟮𝟬𝟳 to explore how our VECTor/CT platform can aid in the design, optimization, and validation of your theranostic protocols for clinical translation. Our VECTor platform can accommodate the widest range of SPECT and PET isotopes, from 20 keV-1.2 MeV, enabling simultaneous in-plane acquisition of SPECT/SPECT, SPECT/PET, and PET/PET imaging protocols. 𝙇𝙚𝙩’𝙨 𝙧𝙚𝙫𝙤𝙡𝙪𝙩𝙞𝙤𝙣𝙞𝙯𝙚 𝙘𝙖𝙣𝙘𝙚𝙧 𝙩𝙝𝙚𝙧𝙖𝙥𝙮 𝙩𝙤𝙜𝙚𝙩𝙝𝙚𝙧! #𝗠𝗜𝗟𝗮𝗯𝘀 #𝗩𝗘𝗖𝗧𝗼𝗿 #𝗣𝗘𝗧 #𝗦𝗣𝗘𝗖𝗧 #𝗖𝗧 #𝗢𝗽𝘁𝗶𝗰𝗮𝗹 #𝗪𝗠𝗜𝗖 #𝗠𝗢𝗠𝗜𝗟 #𝗽𝗿𝗲𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹𝗶𝗺𝗮𝗴𝗶𝗻𝗴 #𝗺𝘂𝗹𝘁𝗶𝗺𝗼𝗱𝗮𝗹 #𝗽𝗿𝗲𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 #𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿𝗶𝗺𝗮𝗴𝗶𝗻𝗴